{"id":"NCT04774380","sponsor":"AstraZeneca","briefTitle":"Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer","officialTitle":"A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-11-11","primaryCompletion":"2023-06-12","completion":"2025-01-02","firstPosted":"2021-03-01","resultsPosted":"2024-08-20","lastUpdate":"2025-05-23"},"enrollment":152,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Extensive-stage Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Durvalumab","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Etoposide","otherNames":[]}],"arms":[{"label":"Durvalumab - (cisplatin or carboplatin) - Etoposide","type":"EXPERIMENTAL"}],"summary":"Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer.","primaryOutcome":{"measure":"Number of Participants With Incidence of Grade 3 or Higher Adverse Events (AEs)","timeFrame":"From first dose of study treatment until 90 days after treatment discontinuation, up to 2.5 years.","effectByArm":[{"arm":"Durvalumab+EP","deltaMin":91,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":18},"locations":{"siteCount":35,"countries":["Bulgaria","Canada","Czechia","Germany","Italy","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419QC00007&amp;attachmentIdentifier=63ae71a0-e925-417e-ad33-008bce95d9c5&amp;fileName=D419QC00007_Redacted_CSP.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419QC00007&amp;attachmentIdentifier=224e7482-7a07-4739-ad7b-c78d01bc5f72&amp;fileName=D419QC00007_Redacted_CSR_synopsis.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419QC00007&amp;attachmentIdentifier=447ccb65-152f-4e82-8bb4-7a2f151dfdb3&amp;fileName=D419QC00007_Redacted_SAP.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":152},"commonTop":["Anaemia","Neutropenia","Nausea","Constipation","Thrombocytopenia"]}}